Theravance, Inc. (NASDAQ: THRX) announced today that GlaxoSmithKline (GSK) has enrolled the first patient in a Phase 2b clinical program with the investigational long-acting beta agonist (LABA) compound, 159797 ('797) from the Beyond Advair collaboration, in patients with mild to moderate asthma. In the collaboration with GSK, the plan is to develop a once-a-day inhaled combination medicine comprised of a LABA and a corticosteroid. This step with '797 is part of the next phase in the collaboration, which will determine the LABA to take into the combination clinical trials program in patients.
